Ticagrelor for acute coronary syndromes

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 11, 2013, Pages 1473-1484

  Bansilal, Sameer ^a   Bonaca, Marc P ^a   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ACS; antiplatelet; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ACUTE CORONARY SYNDROME; BLEEDING TIME; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN ISCHEMIA; CARDIOPULMONARY FUNCTION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DEATH; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RISK REDUCTION; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADENOSINE; ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MYOCARDIAL INFARCTION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; STROKE; TICLOPIDINE;

EID: 84887365965     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2013.839205     Document Type: Review

References (55)

1. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics-2013 update a report from the American Heart Association. Circulation 127(1), e6-e245 (2012
2. Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 381(9872), 1107-1115 (2013
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001
4. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009
5. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007
6. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009
7. Jneid H, Anderson JL, Wright RS et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline and replacing the2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 60(7), 645-681 (2012
8. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33(20), 2569-2619 (2012
9. Vandvik PO, Lincoff AM, Gore JM et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e637S-668S (2012
10. Sangkuhl K, Shuldiner AR, Klein TE, Altman RB. Platelet aggregation pathway. Pharmacogenet. Genomics 21(8), 516-521 (2011
11. Husted S, van Giezen JJ. Ticagrelor: The first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc. Ther. 27(4), 259-274 (2009
12. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31(2), 195-204 (2005
13. Peters G RG. Single-dose pharmacokinetics and pharmacodynamics of AZD6140-An ora reversible ADP receptor antagonist. Haematoligica 989, 14-15 (2004
14. Peters GR BK, Winter HR. Multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZD6140. Eur. Heart J. 27(P4556) (2006
15. Butler K TR. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, exhibits linear pharmacokinetics following multiple doses in healthy subjects, with greater and less variable inhibition of platelet aggregation compared with clopidogrel. Eur. Heart J. 15, e684-e685, Abstract 562 (2008
16. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27(9), 1038-1047 (2006
17. Cannon CP, Husted S, Harrington RA et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol. 50(19), 1844-1851 (2007
18. Storey RF, Husted S, Harrington RA et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 50(19), 1852-1856 (2007
19. Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation 120(25), 2577-2585 (2009
20. Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study. Circulation 121(10), 1188-1199 (2010
21. Husted SE, Storey RF, Bliden K et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: Results from the ONSET-OFFSET and RESPOND studies. Clin. Pharmacokinet. 51(6), 397-409 (2012
22. Alexopoulos D, Xanthopoulou I, Plakomyti TE, Goudas P, Koutroulia E, Goumenos D. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am. J. Kidney Dis. 60(2), 332-333 (2012
23. Becker RC, Bassand JP, Budaj A et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur. Heart J. 32(23), 2933-2944 (2011
24. Quinlan DJ, Eikelboom JW, Goodman SG et al. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. Eur. Heart J. 32(18), 2256-2265 (2011
25. Kohli P, Wallentin L, Reyes E et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation 127(6), 673-680 (2013
26. Cannon CP, Harrington RA, James S et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet 375(9711), 283-293 (2010
27. James SK, Roe MT, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: Substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 342, d3527 (2011
28. Steg PG, James S, Harrington RA et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122(21), 2131-2141 (2010
29. Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J. Am. Coll. Cardiol. 57(6), 672-684 (2011
30. Varenhorst C, Alstrom U, Scirica BM et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J. Am. Coll. Cardiol. 60(17), 1623-1630 (2012
31. James SK, Storey RF, Khurmi NS et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 125(23), 2914-2921 (2012
32. Patel MR, Becker RC, Wojdyla DM et al. cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared to clopidogrel: Data from the PLATO trial. Circulation 124, A14299 (2011
33. James S, Budaj A, Aylward P et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122(11), 1056-1067 (2010
34. James S, Angiolillo DJ, Cornel JH et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur. Heart J. 31(24), 3006-3016 (2010
35. Husted S, James S, Becker RC et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: A substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ. Cardiovasc. Qual. Outcomes 5(5), 680-688 (2012
36. Cornel JH, Becker RC, Goodman SG et al. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J. 164(3), 334-342 e331 (2012
37. Storey RF, Angiolillo DJ, Patil SB et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J. Am. Coll. Cardiol. 56(18), 1456-1462 (2010
38. Storey RF, Becker RC, Harrington RA et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur. Heart J. 32(23), 2945-2953 (2011
39. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J. Am. Coll. Cardiol. 61(7), 723-727 (2013
40. Scirica BM, Cannon CP, Emanuelsson H et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: Results of the continuous electrocardiographic assessment substudy. J. Am. Coll. Cardiol. 57(19), 1908-1916 (2011
41. van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bjorkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J. Cardiovasc. Pharmacol. Ther. 17(2), 164-172 (2012
42. Storey RF, Steg PG, James SK, Husted S, Cannon CP, Becker R, Ycas J, Asenblad N, Kilhamn J, Wallentin L. Reduction in pulmonary adverse events and associated sepsis and mortality in acute coronary syndrome patients treated with ticagrelor compared to clopidogrel: A post hoc analysis of the PLATO Study. J. Am. Coll. Cardiol. 59(13), E482 (2012
43. Alexopoulos D, Xanthopoulou I, Gkizas V et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 5(6), 797-804 (2012
44. Parodi G, Valenti R, Bellandi B et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J. Am. Coll. Cardiol. 61(15), 1601-1606 (2013
45. Bhatt DL, Stone GW, Mahaffey KW et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl J. Med. 368(14), 1303-1313 (2013
46. Mahaffey KW, Wojdyla DM, Carroll K et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124(5), 544-554 (2011
47. Kohli P UJ, Murphy SA, Antman EA, Braunwald E, Wiviott SD. Discharge aspirin dose and clinical outcomes in patients with ACS: An analysis from the TRITON-TIMI 38 study. J. Am. Coll. Cardiol. 59(13s1), E342 (2012
48. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: Results from the PLATO study. Eur. Heart J. 34(3), 220-228 (2013
49. Mega JL, Hochholzer W, Frelinger AL, III et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306(20), 2221-2228 (2011
50. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366(1), 9-19 (2012
51. Morrow DA, Braunwald E, Bonaca MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366(15), 1404-1413 (2012
52. Tricoci P, Huang Z, Held C et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366(1), 20-33 (2012
53. Montalescot G, Sideris G, Meuleman C et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48(5), 931-938 (2006
54. Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153(1), 66 e69-16 (2007
55. Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist. J. Clin. Pharmacol. 50(1), 27-35 (2010